[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-338156-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-338156-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","metabolic-function-and-therapeutic-potential-of-cd147-for-hematological-malignancies-an-overview-review","Metabolic Function and Therapeutic Potential of CD147 for Hematological Malignancies: An Overview - Review","","Hematological malignancies comprise diverse neoplastic disorders of lymphoid and hematopoietic tissues, including leukemias, Hodgkin and non-Hodgkin lymphomas, and multiple myeloma. Metabolic adaptation and immune escape support proliferation and survival while promoting therapeutic drug resistance. The review emphasizes that targeting metabolic pathways is emerging as a strategy in hematopoietic neoplasms, especially acute myeloid leukemia and multiple myeloma. CD147 (EMMPRIN/Basigin) is highlighted as a candidate involved in metabolic reprogramming and influences tumor microenvironment, progression, and targeted therapy development.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/metabolic-function-and-therapeutic-potential-of-cd147-for-hematological-malignancies-an-overview-review/338156/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/metabolic-function-and-therapeutic-potential-of-cd147-for-hematological-malignancies-an-overview-review/338156.png","ImageObject",300,407,{"name":42,"@type":43},"Levi","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-23","2026-09-21",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",7,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What are hematological malignancies, and why does metabolism matter in them?","Question",{"text":63,"@type":64},"They are diverse cancers of blood and lymphatic tissues, including leukemias, lymphomas, and multiple myeloma. Metabolic adaptation and immune escape drive proliferation, survival, and therapeutic drug resistance.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How does the Warburg effect relate to hematological malignancies?",{"text":68,"@type":64},"Tumor cells increase glucose consumption through aerobic glycolysis, producing and accumulating lactate. The review notes strategies that inhibit lactate production or lactate transport to target this effect.",{"name":70,"@type":61,"acceptedAnswer":71},"What role does CD147 play in these cancers?",{"text":72,"@type":64},"CD147 is a multifunctional glycoprotein whose overexpression correlates with poor prognosis. It interacts with membrane proteins involved in metabolic regulation, supporting signaling, growth, metastasis, and metabolic reprogramming.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},338156,1790685414,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":117,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":104,"preview_page_count":33,"preview_urls":144},7971461740909,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","Review  \nMetabolic Function and Therapeutic Potential of CD147 for Hematological Malignancies: An Overview  \nIsabella Spinello, Catherine Labbaye and Ernestina Saulle *  \nCitation: Spinello, I.; Labbaye, C.; Saulle, E. Metabolic Function and Therapeutic Potential of CD147 for Hematological Malignancies: An Overview. Int. J. Mol. Sci. 2024, 25, 9178. [https://doi.org/10.3390/](https://doi.org/10.3390/)[ ](https://doi.org/10.3390/)ijms25179178  \nAcademic Editor: Albrecht Reichle  \nReceived: 29 July 2024  \nRevised: 21 August 2024  \nAccepted: 22 August 2024  \nPublished: 23 August 2024  \nCopyright: © 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ([https://](https://)[ ](https://)[creativecommons.org/licenses/by/](creativecommons.org/licenses/by/)[ ](creativecommons.org/licenses/by/)[4.0/](4.0/)) .  \nIstituto Superiore di Sanità, National Center for Drug Research and Evaluation, 00161 Rome, Italy;  \n[isabella.spinello@iss.it](isabella.spinello@iss.it) (I.S.); [catherine.labbaye@iss.it](catherine.labbaye@iss.it) (C.L.)  \n* Correspondence: [ernestina.saulle@iss.it](ernestina.saulle@iss.it)  \nAbstract: Hematological malignancies refer to a heterogeneous group of neoplastic conditions of lymphoid and hematopoietic tissues classified in leukemias, Hodgkin and non-Hodgkin lymphomasand multiple myeloma, according to their presumed cell of origin, genetic abnormalities, and clinical features. Metabolic adaptation and immune escape, which influence various cellular functions, including the proliferation and survival of hematological malignant tumor cells, are major aspects of these malignancies that lead to therapeutic drug resistance. Targeting specific metabolic pathways is emerging as a novel therapeutic strategy in hematopoietic neoplasms, particularly in acute myeloid leukemia and multiple myeloma. In this context, CD147, also known as extracellular matrix metalloproteinase inducer (EMMPRIN) or Basigin, is one target candidate involved in reprograming metabolism in different cancer cells, including hematological malignant tumor cells. CD147 overexpression significantly contributes to the metabolic transformation of these cancer cells, by mediating signaling pathway, growth, metastasis and metabolic reprogramming, through its interaction, director not, with various membrane proteins related to metabolic regulation, including monocarboxylate transporters, integrins, P-glycoprotein, and glucose transporter 1 . This review explores the metabolic functions of CD147 and its impact on the tumor microenvironment, influencing the progression and neoplastic transformation of leukemias, myeloma, and lymphomas. Furthermore, we highlight new opportunities for the development of targeted therapies against CD147, potentially improving the treatment of hematologic malignancies.  \nKeywords: hematological malignancies; metabolism; CD147  \n1. Introduction  \nHematologic malignancies (HMs) represent a wide range of malignant tumors of the blood and lymphatic system that share pathological alterations capable of inducing radical transformations in cells, characterized by genetic, histological, and metabolic alterations associated with uncontrolled cell proliferation and high resistance to cell death [1–5] . From three main groups including leukemias, lymphomas, and multiple myeloma, HM can be categorized into different subgroups, such as acute leukemias, chronic leukemias, myelodysplastic syndromes (MDSs), myeloproliferative neoplasms (MPNs), non-Hodgkin lymphomas, and classic Hodgkin lymphomas [2–5] . Aberrant metabolism can significantly affect the immune microenvironment and thus modulate the immune cellular response of hematological malignant tumor cells, contributing to disease progression [6] .  \nIncreasing progress has been made for the treatment of HMs, involving drugs classified as chemotherapy agents, whose","cbCaiaeBmvcK89AK","https://ap.wps.com/l/cbCaiaeBmvcK89AK","pdf",776182,"English","# Abstract\n# Introduction\n## Metabolic changes in hematological malignancies\n## CD147 (EMMPRIN/Basigin) and metabolic regulation","[{\"question\":\"What are hematological malignancies, and why does metabolism matter in them?\",\"answer\":\"They are diverse cancers of blood and lymphatic tissues, including leukemias, lymphomas, and multiple myeloma. Metabolic adaptation and immune escape drive proliferation, survival, and therapeutic drug resistance.\"},{\"question\":\"How does the Warburg effect relate to hematological malignancies?\",\"answer\":\"Tumor cells increase glucose consumption through aerobic glycolysis, producing and accumulating lactate. The review notes strategies that inhibit lactate production or lactate transport to target this effect.\"},{\"question\":\"What role does CD147 play in these cancers?\",\"answer\":\"CD147 is a multifunctional glycoprotein whose overexpression correlates with poor prognosis. It interacts with membrane proteins involved in metabolic regulation, supporting signaling, growth, metastasis, and metabolic reprogramming.\"}]","Metabolic Function and Therapeutic Potential of CD147 for Hematological Malignancies: An Overview - Review | PDF",1790022279,[145,149,153,157],{"page_no":22,"url":146,"width":147,"height":148},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/fc6a3f2630f7c33d4f096b8bb6b59f8e.webp",983,1390,{"page_no":26,"url":150,"width":151,"height":152},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/33c36f4e3a5dc15adaeec94960b8ee4a.webp",982,1388,{"page_no":30,"url":154,"width":155,"height":156},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/911271857d643ae04a2dacdf096bb677.webp",981,1387,{"page_no":33,"url":158,"width":159,"height":160},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d529fe743ad3c86651e3d9f7028de8da.webp",980,1385]